1. Home
  2. RGNX
  3. RGNX News

Latest REGENXBIO Inc. (RGNX) News on October 25, 2025

REGENXBIO to Participate in Upcoming Investor Conferences
RGNX

PR Newswire

10 days ago

REGENXBIO to Participate in Upcoming Investor Conferences

REGENXBIO Announces Presentation at the American Academy of Ophthalmology 2025 Annual Meeting
RGNX

PR Newswire

16 days ago

REGENXBIO Announces Presentation at the American Academy of Ophthalmology 2025 Annual Meeting

REGENXBIO Announces Completion of Enrollment in Pivotal Trials of Subretinal Surabgene Lomparvovec for Wet AMD
RGNX

PR Newswire

19 days ago

REGENXBIO Announces Completion of Enrollment in Pivotal Trials of Subretinal Surabgene Lomparvovec for Wet AMD

Regenxbio Unveils 12-Month Data For Gene Therapy Soon After FDA Delays Review Date
RGNX

Benzinga

2 months ago

Regenxbio Unveils 12-Month Data For Gene Therapy Soon After FDA Delays Review Date

RGNX

MT Newswires

2 months ago

Sector Update: Health Care Stocks Mixed Pre-Bell Friday

RGNX

MT Newswires

2 months ago

Regenxbio Says Longer-Term Trial Data Show RGX-121's Ability to Improve Outcomes for Hunter Syndrome Patients

REGENXBIO Presents Positive Twelve-Month Pivotal Data from Phase I/II/III CAMPSIITE® Trial of RGX-121 for Treatment of MPS II
RGNX

PR Newswire

2 months ago

REGENXBIO Presents Positive Twelve-Month Pivotal Data from Phase I/II/III CAMPSIITE® Trial of RGX-121 for Treatment of MPS II

Gene Therapy Was the Biggest Idea in Biotech. Now It Has Lost Support on Wall Street.
RGNX

Barrons.com

4 months ago

Gene Therapy Was the Biggest Idea in Biotech. Now It Has Lost Support on Wall Street.

Gene Therapy Has Lost Support on Wall Street. There’s Still Hope for Big Cures.
RGNX

Barrons.com

4 months ago

Gene Therapy Has Lost Support on Wall Street. There’s Still Hope for Big Cures.

Otsuka tops Vera with kidney drug data; Regenxbio sinks on Duchenne update
RGNX

BioPharma Dive

5 months ago

Otsuka tops Vera with kidney drug data; Regenxbio sinks on Duchenne update

RGNX

MT Newswires

5 months ago

Regenxbio Reports 'Positive' Interim Data From Duchenne Muscular Dystrophy Trial

REGENXBIO REPORTS NEW POSITIVE FUNCTIONAL DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202
RGNX

PR Newswire

5 months ago

REGENXBIO REPORTS NEW POSITIVE FUNCTIONAL DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202

REGENXBIO to Host Webcast Discussing Interim Functional Data from the Phase I/II AFFINITY DUCHENNE® Trial of RGX-202
RGNX

PR Newswire

5 months ago

REGENXBIO to Host Webcast Discussing Interim Functional Data from the Phase I/II AFFINITY DUCHENNE® Trial of RGX-202

Tourmaline shares fall on Phase 2 data; Schrödinger cuts staff
RGNX

BioPharma Dive

5 months ago

Tourmaline shares fall on Phase 2 data; Schrödinger cuts staff

RGNX

MT Newswires

5 months ago

Regenxbio Signs Royalty Deal Worth Up to $250 Million With Healthcare Royalty

REGENXBIO Announces Strategic Royalty Monetization Agreement for Up to $250 Million
RGNX

PR Newswire

5 months ago

REGENXBIO Announces Strategic Royalty Monetization Agreement for Up to $250 Million

Earnings Miss: REGENXBIO Inc. Missed EPS By 64% And Analysts Are Revising Their Forecasts
RGNX

Simply Wall St.

5 months ago

Earnings Miss: REGENXBIO Inc. Missed EPS By 64% And Analysts Are Revising Their Forecasts

FDA Accepts Biologics License Application for Mucopolysaccharidosis II Treatment
RGNX

PR Newswire

5 months ago

FDA Accepts Biologics License Application for Mucopolysaccharidosis II Treatment

RGNX

Thomson Reuters StreetEvents

5 months ago

Q1 2025 Regenxbio Inc Earnings Call

RGNX

MT Newswires

5 months ago

Regenxbio Says Potential Hunter Syndrome Treatment Granted FDA Priority Review

REGENXBIO Announces FDA Acceptance and Priority Review of the BLA for RGX-121 for MPS II
RGNX

PR Newswire

5 months ago

REGENXBIO Announces FDA Acceptance and Priority Review of the BLA for RGX-121 for MPS II

Regenxbio Inc (RGNX) Q1 2025 Earnings Call Highlights: Strategic Partnerships and Financial ...
RGNX

GuruFocus.com

5 months ago

Regenxbio Inc (RGNX) Q1 2025 Earnings Call Highlights: Strategic Partnerships and Financial ...

Regenxbio (RGNX) Q1 Earnings and Revenues Lag Estimates
RGNX

Zacks

5 months ago

Regenxbio (RGNX) Q1 Earnings and Revenues Lag Estimates

RGNX

Associated Press Finance

5 months ago

Regenxbio: Q1 Earnings Snapshot

REGENXBIO Reports First Quarter 2025 Financial Results and Recent Operational Highlights
RGNX

PR Newswire

5 months ago

REGENXBIO Reports First Quarter 2025 Financial Results and Recent Operational Highlights

What To Expect From Regenxbio Inc (RGNX) Q1 2025 Earnings
RGNX

GuruFocus.com

6 months ago

What To Expect From Regenxbio Inc (RGNX) Q1 2025 Earnings

REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 28th Annual Meeting
RGNX

PR Newswire

6 months ago

REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 28th Annual Meeting

REGENXBIO to Participate in Upcoming Investor Conferences
RGNX

PR Newswire

6 months ago

REGENXBIO to Participate in Upcoming Investor Conferences

Regenxbio (RGNX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
RGNX

Zacks

6 months ago

Regenxbio (RGNX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

REGENXBIO to Host Conference Call on May 12 to Discuss First Quarter 2025 Financial Results and Recent Operational Highlights
RGNX

PR Newswire

6 months ago

REGENXBIO to Host Conference Call on May 12 to Discuss First Quarter 2025 Financial Results and Recent Operational Highlights

Trump’s FDA Sends a Bullish Signal to Biotech
RGNX

The Wall Street Journal

6 months ago

Trump’s FDA Sends a Bullish Signal to Biotech

RGNX

MT Newswires

7 months ago

RBC Cuts Price Target on REGENXBIO to $25 From $30, Keeps Outperform, Speculative Risk

Biotech stocks slide as Marks resignation seen being negative for sector
RGNX

TipRanks

7 months ago

Biotech stocks slide as Marks resignation seen being negative for sector

Regenxbio’s DMD gene therapy drives 122.3% biomarker uptick in three-year-old
RGNX

Clinical Trials Arena

7 months ago

Regenxbio’s DMD gene therapy drives 122.3% biomarker uptick in three-year-old

RGNX

MT Newswires

7 months ago

Regenxbio Says New Data Support Potential Gene Therapy for Duchenne Muscular Dystrophy

REGENXBIO REPORTS POSITIVE BIOMARKER DATA FROM AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY
RGNX

PR Newswire

7 months ago

REGENXBIO REPORTS POSITIVE BIOMARKER DATA FROM AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY

REGENXBIO Inc. (NASDAQ:RGNX) Is About To Turn The Corner
RGNX

Simply Wall St.

7 months ago

REGENXBIO Inc. (NASDAQ:RGNX) Is About To Turn The Corner

RGNX

Thomson Reuters StreetEvents

7 months ago

Q4 2024 Regenxbio Inc Earnings Call

Regenxbio Inc (RGNX) Q4 2024 Earnings Call Highlights: Strategic Advances and Financial Resilience
RGNX

GuruFocus.com

7 months ago

Regenxbio Inc (RGNX) Q4 2024 Earnings Call Highlights: Strategic Advances and Financial Resilience

Regenxbio (RGNX) Reports Q4 Loss, Lags Revenue Estimates
RGNX

Zacks

7 months ago

Regenxbio (RGNX) Reports Q4 Loss, Lags Revenue Estimates

RGNX

Associated Press Finance

7 months ago

Regenxbio: Q4 Earnings Snapshot

REGENXBIO Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Updates
RGNX

PR Newswire

7 months ago

REGENXBIO Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Updates

REGENXBIO Announces Presentations at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
RGNX

PR Newswire

8 months ago

REGENXBIO Announces Presentations at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Will Regenxbio (RGNX) Report Negative Earnings Next Week? What You Should Know
RGNX

Zacks

8 months ago

Will Regenxbio (RGNX) Report Negative Earnings Next Week? What You Should Know

Jim Cramer on REGENXBIO Inc. (RGNX): ‘This Thing Just Does Nothing But Go Down’
RGNX

Insider Monkey

8 months ago

Jim Cramer on REGENXBIO Inc. (RGNX): ‘This Thing Just Does Nothing But Go Down’

RGNX

MT Newswires

8 months ago

Regenxbio Closes Partnership With Nippon Shinyaku

REGENXBIO Announces Closing of Strategic Partnership with Nippon Shinyaku for MPS Diseases
RGNX

PR Newswire

8 months ago

REGENXBIO Announces Closing of Strategic Partnership with Nippon Shinyaku for MPS Diseases

REGENXBIO to Host Conference Call on March 13 to Discuss Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Highlights
RGNX

PR Newswire

8 months ago

REGENXBIO to Host Conference Call on March 13 to Discuss Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Highlights

REGENXBIO to Participate in Upcoming Investor Conferences
RGNX

PR Newswire

8 months ago

REGENXBIO to Participate in Upcoming Investor Conferences

Castle Biosciences, Inc. (CSTL) Reports Next Week: Wall Street Expects Earnings Growth
RGNX

Zacks

8 months ago

Castle Biosciences, Inc. (CSTL) Reports Next Week: Wall Street Expects Earnings Growth

Regenxbio's Gene Therapy Outlook Dims As Rival Treatments Gain Ground, Goldman Sachs Warns
RGNX

Benzinga

8 months ago

Regenxbio's Gene Therapy Outlook Dims As Rival Treatments Gain Ground, Goldman Sachs Warns

RGNX

MT Newswires

8 months ago

Regenxbio Shares Fall After Downgrade From Goldman Sachs

RGNX

MT Newswires

8 months ago

Goldman Sachs Downgrades REGENXBIO to Neutral From Buy, Cuts Price Target to $14 From $38

Wall Street Analysts Think Regenxbio (RGNX) Could Surge 333.01%: Read This Before Placing a Bet
RGNX

Zacks

8 months ago

Wall Street Analysts Think Regenxbio (RGNX) Could Surge 333.01%: Read This Before Placing a Bet

With 71% ownership of the shares, REGENXBIO Inc. (NASDAQ:RGNX) is heavily dominated by institutional owners
RGNX

Simply Wall St.

9 months ago

With 71% ownership of the shares, REGENXBIO Inc. (NASDAQ:RGNX) is heavily dominated by institutional owners

REGENXBIO Announces Presentations of RGX-121 at the 21st Annual WORLDSymposium 2025
RGNX

PR Newswire

9 months ago

REGENXBIO Announces Presentations of RGX-121 at the 21st Annual WORLDSymposium 2025

Wall Street Analysts See a 357.36% Upside in Regenxbio (RGNX): Can the Stock Really Move This High?
RGNX

Zacks

9 months ago

Wall Street Analysts See a 357.36% Upside in Regenxbio (RGNX): Can the Stock Really Move This High?

Gene therapies have been uneven for DMD — but these companies hope to turn the tide
RGNX

Pharma Voice

9 months ago

Gene therapies have been uneven for DMD — but these companies hope to turn the tide

Regenxbio and Nippon Shinyaku forge $810m gene therapy deal
RGNX

Pharmaceutical Technology

9 months ago

Regenxbio and Nippon Shinyaku forge $810m gene therapy deal

Regenxbio licenses gene therapies to Japan’s Nippon Shinyaku
RGNX

BioPharma Dive

9 months ago

Regenxbio licenses gene therapies to Japan’s Nippon Shinyaku

RGNX

MT Newswires

9 months ago

REGENXBIO, Nippon Shinyaku Partner to Advance Drug Candidates for Certain Genetic Disorders in US, Asia

REGENXBIO and Nippon Shinyaku Announce Exclusive Partnership to Develop and Commercialize RGX-121 and RGX-111 for MPS Diseases
RGNX

PR Newswire

9 months ago

REGENXBIO and Nippon Shinyaku Announce Exclusive Partnership to Develop and Commercialize RGX-121 and RGX-111 for MPS Diseases

AbbVie and REGENXBIO Announce Updates on the ABBV-RGX-314 Clinical Program
RGNX

PR Newswire

9 months ago

AbbVie and REGENXBIO Announce Updates on the ABBV-RGX-314 Clinical Program

Regenxbio price target lowered to $22 from $25 at BofA
RGNX

TipRanks

10 months ago

Regenxbio price target lowered to $22 from $25 at BofA

RGNX

MT Newswires

10 months ago

BofA Securities Adjusts Price Target on REGENXBIO to $22 From $25, Maintains Buy Rating

RGNX

MT Newswires

10 months ago

RBC Lowers Price Target on REGENXBIO to $30 From $35, Keeps Outperform, Speculative Risk

RGNX

Argus Research

10 months ago

RGNX: Lowering target price to $8.00

RGNX

Argus Research

10 months ago

RGNX: Rating increased to a HOLD

RGNX

Argus Research

10 months ago

RGNX: Raising target price to $8.00

Apollo Global Management and Workday Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600
RGNX

PR Newswire

a year ago

Apollo Global Management and Workday Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

RGNX

Argus Research

a year ago

RGNX: Lowering target price to $7.00

RGNX

Argus Research

a year ago

RGNX: Rating decreased to a SELL

Regenxbio eyes 2026 filing for Duchenne muscular dystrophy gene therapy
RGNX

Pharmaceutical Technology

a year ago

Regenxbio eyes 2026 filing for Duchenne muscular dystrophy gene therapy

RGNX

MT Newswires

a year ago

Update: Regenxbio Shares Rise After Positive Phase I/II Data on RGX-202 Gene Therapy for Duchenne Muscular Dystrophy

RGNX

MT Newswires

a year ago

Sector Update: Health Care Stocks Mixed Premarket Monday

RGNX

MT Newswires

a year ago

Regenxbio Reports Positive Phase I/II Data on RGX-202 Gene Therapy for Duchenne Muscular Dystrophy - Shares Up Pre-Bell

REGENXBIO INITIATES PIVOTAL PHASE OF AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY AND REPORTS POSITIVE FUNCTIONAL DATA
RGNX

PR Newswire

a year ago

REGENXBIO INITIATES PIVOTAL PHASE OF AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY AND REPORTS POSITIVE FUNCTIONAL DATA

FDA endorses speedy approval path for Regenxbio Duchenne gene therapy
RGNX

BioPharma Dive

a year ago

FDA endorses speedy approval path for Regenxbio Duchenne gene therapy

REGENXBIO to Host Webcast Discussing Pivotal Program and First Functional Data from the AFFINITY DUCHENNE® Trial of RGX-202
RGNX

PR Newswire

a year ago

REGENXBIO to Host Webcast Discussing Pivotal Program and First Functional Data from the AFFINITY DUCHENNE® Trial of RGX-202

RGNX

Argus Research

a year ago

RGNX: Raising target price to $11.00

Analysts Have Made A Financial Statement On REGENXBIO Inc.'s (NASDAQ:RGNX) Third-Quarter Report
RGNX

Simply Wall St.

a year ago

Analysts Have Made A Financial Statement On REGENXBIO Inc.'s (NASDAQ:RGNX) Third-Quarter Report

REGENXBIO Third Quarter 2024 Earnings: EPS Misses Expectations
RGNX

Simply Wall St.

a year ago

REGENXBIO Third Quarter 2024 Earnings: EPS Misses Expectations

Regenxbio Inc (RGNX) Q3 2024 Earnings Call Highlights: Advancements in Gene Therapy and ...
RGNX

GuruFocus.com

a year ago

Regenxbio Inc (RGNX) Q3 2024 Earnings Call Highlights: Advancements in Gene Therapy and ...

Regenxbio (RGNX) Reports Q3 Loss, Tops Revenue Estimates
RGNX

Zacks

a year ago

Regenxbio (RGNX) Reports Q3 Loss, Tops Revenue Estimates

RGNX

Associated Press Finance

a year ago

Regenxbio: Q3 Earnings Snapshot

REGENXBIO Reports Third Quarter 2024 Financial Results and Recent Operational Updates
RGNX

PR Newswire

a year ago

REGENXBIO Reports Third Quarter 2024 Financial Results and Recent Operational Updates

RGNX

Argus Research

a year ago

RGNX: Lowering target price to $9.00

Regenxbio Inc (RGNX) Q3 2024: Everything You Need To Know Ahead Of Earnings
RGNX

GuruFocus.com

a year ago

Regenxbio Inc (RGNX) Q3 2024: Everything You Need To Know Ahead Of Earnings

REGENXBIO to Participate in Upcoming Investor Conferences
RGNX

PR Newswire

a year ago

REGENXBIO to Participate in Upcoming Investor Conferences

REGENXBIO to Host Conference Call on November 6 to Discuss Third Quarter 2024 Financial Results and Recent Operational Highlights
RGNX

PR Newswire

a year ago

REGENXBIO to Host Conference Call on November 6 to Discuss Third Quarter 2024 Financial Results and Recent Operational Highlights

The past five years for REGENXBIO (NASDAQ:RGNX) investors has not been profitable
RGNX

Simply Wall St.

a year ago

The past five years for REGENXBIO (NASDAQ:RGNX) investors has not been profitable

RGNX

MT Newswires

a year ago

Regenxbio Reports 97% Reduction in Injection Need for Wet AMD; Shares Rise Pre-Bell

REGENXBIO Presents Positive Data from the Phase II Study of Subretinal ABBV-RGX-314 in Patients with Bilateral Wet AMD at AAO 2024
RGNX

PR Newswire

a year ago

REGENXBIO Presents Positive Data from the Phase II Study of Subretinal ABBV-RGX-314 in Patients with Bilateral Wet AMD at AAO 2024

REGENXBIO Announces Presentations at the American Academy of Ophthalmology 2024 Annual Meeting
RGNX

PR Newswire

a year ago

REGENXBIO Announces Presentations at the American Academy of Ophthalmology 2024 Annual Meeting

JPMorgan Chase & Co. Reduces Stake in Regenxbio Inc
RGNX

GuruFocus.com

a year ago

JPMorgan Chase & Co. Reduces Stake in Regenxbio Inc

RGNX

Argus Research

a year ago

RGNX: Rating increased to a HOLD

REGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines Conference
RGNX

PR Newswire

a year ago

REGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines Conference

RGNX

MT Newswires

a year ago

Regenxbio Names Mitchell Chan CFO

REGENXBIO Appoints Mitchell Chan as Chief Financial Officer
RGNX

PR Newswire

a year ago

REGENXBIO Appoints Mitchell Chan as Chief Financial Officer

RegenxBio touts positive data for rare disease drug RGX-121
RGNX

Pharmaceutical Technology

a year ago

RegenxBio touts positive data for rare disease drug RGX-121

Share on Social Networks: